O’Brien, Neil A. http://orcid.org/0000-0001-7408-1091
McDermott, Martina S. J.
Conklin, Dylan
Luo, Tong
Ayala, Raul
Salgar, Suruchi
Chau, Kevin
DiTomaso, Emmanuelle
Babbar, Naveen
Su, Faye
Gaither, Alex
Hurvitz, Sara A.
Linnartz, Ronald
Rose, Kristine
Hirawat, Samit
Slamon, Dennis J.
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
DOD Peer Reviewed Cancer Research Program (W81XWH-11-1-0104)
Article History
Received: 11 February 2020
Accepted: 23 July 2020
First Online: 14 August 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: Neil A. O’Brien: Novartis—research funding.Martina S.J. McDermott: none to declareDylan Conklin: none to declareTong Luo: none to declareRaul Ayala: none to declareSuruchi Salgar: none to declareKevin Chau: none to declareEmmanuelle DiTomaso: former Novartis employeeNaveen Babbar: full-time Novartis employeeFaye Su: full-time Novartis employeeAlex Gaither: former Novartis employeeSara A. Hurvitz: clinical research funding paid to UCLA from Eli Lilly, Novartis, and PfizerRonald Linnartz: full-time Novartis employeeKristine Rose: full-time Novartis employeeSamit Hirawat: former Novartis employeeDennis J. Slamon: Pfizer—stock ownership, research funding, and travel expenses. Novartis—honoraria, consulting advisory role, research funding, and travel expenses. Eli Lilly—consulting advisory role